Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Leibowitz

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Society of General Physiologists Series|January 1, 1987
State-dependent modification of sodium channels by lipid-soluble agonistsB Hille, M D Leibowitz, J B Sutro, et al.
Neuron|August 1, 1988
Agonists that suppress M-current elicit phosphoinositide turnover and Ca2+ transients, but these events do not explain M-current suppressionP J Pfaffinger, M D Leibowitz, E M Subers, et al.
Biochemical and Biophysical Research Communications|July 16, 1996
Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2A Elbrecht, Y Chen, C A Cullinan, et al.
Molecular Pharmacology|December 1, 1992
High affinity block of myocardial L-type calcium channels by the spider toxin omega-Aga-toxin IIIA: advantages over 1,4-dihydropyridinesC J Cohen, E A Ertel, M M Smith, et al.
Gastroenterologie Clinique Et Biologique|September 30, 2000
[Peroxisome proliferator-activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease]L Dubuquoy, C Bourdon, M Peuchmaur, et al.
Endocrinology|October 1, 1996
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db miceJ Berger, P Bailey, C Biswas, et al.
Molecular Pharmacology|March 22, 2001
Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodentsH Singh Ahuja, S Liu, D L Crombie, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
Design and synthesis of benzofused heterocyclic RXR modulatorsD L Gernert, D A Neel, M F Boehm, et al.
Diabetes|January 1, 1995
A novel insulin secretagogue is a phosphodiesterase inhibitorM D Leibowitz, C Biswas, E J Brady, et al.
The Journal of Experimental Medicine|April 3, 2001
Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategiesP Desreumaux, L Dubuquoy, S Nutten, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Society of General Physiologists Series|January 1, 1987
State-dependent modification of sodium channels by lipid-soluble agonistsB Hille, M D Leibowitz, J B Sutro, et al.
Neuron|August 1, 1988
Agonists that suppress M-current elicit phosphoinositide turnover and Ca2+ transients, but these events do not explain M-current suppressionP J Pfaffinger, M D Leibowitz, E M Subers, et al.
Biochemical and Biophysical Research Communications|July 16, 1996
Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2A Elbrecht, Y Chen, C A Cullinan, et al.
Molecular Pharmacology|December 1, 1992
High affinity block of myocardial L-type calcium channels by the spider toxin omega-Aga-toxin IIIA: advantages over 1,4-dihydropyridinesC J Cohen, E A Ertel, M M Smith, et al.
Gastroenterologie Clinique Et Biologique|September 30, 2000
[Peroxisome proliferator-activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease]L Dubuquoy, C Bourdon, M Peuchmaur, et al.
Endocrinology|October 1, 1996
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db miceJ Berger, P Bailey, C Biswas, et al.
Molecular Pharmacology|March 22, 2001
Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodentsH Singh Ahuja, S Liu, D L Crombie, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
Design and synthesis of benzofused heterocyclic RXR modulatorsD L Gernert, D A Neel, M F Boehm, et al.
Diabetes|January 1, 1995
A novel insulin secretagogue is a phosphodiesterase inhibitorM D Leibowitz, C Biswas, E J Brady, et al.
The Journal of Experimental Medicine|April 3, 2001
Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategiesP Desreumaux, L Dubuquoy, S Nutten, et al.
Pageof 3